Replies to post #57504 on NorthWest Biotherapeutics Inc (NWBO)

[GoodGuyBill]

Sorry I don't buy this.
Please show me exactly where NWBO said that THIS was good and not bad

Everyone knows you don't buy anything NWBO does or it stock. Here's a few of the quotes. Twist away my friend.

NWBO Press Release on 1/8/2016:

NW Bio is not aware of any fundamental Company-related reason for the substantial decline in the price of the Company’s stock at this time.

The most recent data from NW Bio’s clinical programs, which was presented at scientific conferences in London and New York in mid-September, was encouraging.

NWBO Press Release on 10/19/2015:

BETHESDA, MD, October 19, 2015 – Northwest Biotherapeutics (NASDAQ: NWBO) (“NW Bio”), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today issued the following statement addressing the recent highly unusual trading activity in the Company’s stock:

NW Bio is not aware of any fundamental reason for the substantial decline in the price of the Company’s stock on Friday, October 16. Indeed, NW Bio presented encouraging clinical data at scientific conferences in London and New York as recently as mid-September.

The Company’s clinical data update included promising ongoing interim survival data from both the Phase I trial of DCVax-Direct in 13 diverse cancers, and the Information Arm of 51 patients who were unable to enroll in the Phase III trial of DCVax-L for newly diagnosed Glioblastoma multiforme (GBM) brain cancer because of apparent early tumor recurrence.

In the DCVax-Direct trial for patients with multiple inoperable metastatic tumors who had failed standard treatments (including multiple different chemotherapy regimens), half of these patients are still alive with survival times now ranging up to 22 months, exceeding expected survival times.

In the DCVax-L Information Arm, for the 25 GBM patients with apparent early tumor recurrence at one of two time points, 40% of the patients have now reached or exceeded approximately 3 years’ survival. This substantially exceeds the expected survival time of about 15 months even for regular GBM patients without early tumor recurrence.

NW Bio noted that the Company’s shares have experienced highly unusual trading activity since the September release of positive data, including especially on Friday, October 16, when more than 2.9 million NW Bio shares were traded, representing five times its recent average daily trading volume. The Company believes this activity is part of an ongoing effort to drive its stock price lower through an orchestrated campaign, including questionable short selling activity. The Company is intensifying its investigation and gathering of evidence.

Form 8K released 8/25/2016::

Yes, the 300 patients are actually enrolled and being treated in the trial.

Also, being in the trial means that the patients are not in the Information Arm, and not in the pseudo-progression arm, each of which are parallel with the trial but outside the trial.

The supposed “confusion” about our enrollment is, once again, certain bloggers and commentators trying to turn good news into bad news about NW Bio and its trial. People familiar with clinical trials are generally aware that screening of patient candidates for eligibility is different than recruitment or enrollment of patients for treatment.

Regarding the information we are submitting for regulatory review: companies do not normally discuss such information when they are in the middle of a regulatory process or dialog, and we do not plan to do so either. We will provide an update when the process is finished and there is something to report.